Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 39 results.
User Information
Export Records
  1. 1.   Hydropersulfides (RSSH) attenuate doxorubicin-induced cardiotoxicity while boosting its anticancer action
  2. Pharoah, Blaze M; Zhang, Chengximeng; Khodade, Vinayak S; Keceli, Gizem; McGinity,Chris; Paolocci, Nazareno; Toscano, John P
  3. Redox Biology. 2023, Feb 04; 60: 102625.
  1. 2.   Nanocomplexes of doxorubicin and DNA fragments for efficient and safe cancer chemotherapy
  2. Mohammad, Saad N; Choi, Yeon Su; Chung, Jee Young; Cedrone,Edward; Neun,Barry; Dobrovolskaia,Marina; Yang, Xiaojing; Guo, Wei; Chew, Yap Ching; Kim, Juwan; Baek, Seunggul; Kim, Ik Soo; Fruman, David A; Kwon, Young Jik
  3. Journal of Controlled Release : official journal of the Controlled Release Society. 2023, Jan; 354: 91-108.
  1. 3.   Heterodimeric IL-15 (hetIL-15) reduces circulating tumor cells and metastasis formation improving chemotherapy and surgery in 4T1 mouse model of TNBC
  2. Stravokefalou, Vasiliki; Stellas, Dimitris; Karaliota,Sevasti; Nagy,Bethany; Valentin, Antonio; Bergamaschi, Cristina; Dimas, Konstantinos; Pavlakis,George
  3. Frontiers in Immunology. 2022, Jan 13; 13: 1014802.
  1. 4.   Pilot Trial AMC-063: Safety and Efficacy of Bortezomib in AIDS-associated Kaposi Sarcoma
  2. Reid, Erin G; Suazo, Adrienne; Lensing, Shelly Y; Dittmer, Dirk P; Ambinder, Richard F; Maldarelli, Frank; Gorelick,Robert; Aboulafia, David M; Mitsuyasu, Ronald; Dickson, Mark A; Wachsman, William
  3. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020, FEB; 26(3): 558-565.
  1. 5.   Eribulin Regresses a Doxorubicin-resistant Dedifferentiated Liposarcoma in a Patient-derived Orthotopic Xenograft Mouse Model
  2. Igarashi, Kentaro; Kawaguchi, Kei; Kiyuna, Tasuku; Miyake, Kentaro; Higuchi, Takashi; Yamamoto, Norio; Hayashi, Katsuhiro; Kimura, Hiroaki; Miwa, Shinji; Singh,Shree Ram; Tsuchiya, Hiroyuki; Hoffman, Robert M
  3. Cancer genomics & proteomics. 2020, Jul-Aug; 17(4): 351-358.
  1. 6.   Pioglitazone, an agonist of PPAR?, reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression
  2. Higuchi, Takashi; Sugisawa, Norihiko; Miyake, Kentaro; Oshiro, Hiromichi; Yamamoto, Norio; Hayashi, Katsuhiro; Kimura, Hiroaki; Miwa, Shinji; Igarashi, Kentaro; Kline,Zoey; Bouvet, Michael; Singh,Shree Ram; Tsuchiya, Hiroyuki; Hoffman, Robert M
  3. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2019, Oct; 118: 109356.
  1. 7.   Eribulin Suppressed Cisplatinum- and Doxorubicin-resistant Recurrent Lung Metastatic Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model
  2. Kiyuna, Tasuku; Tome, Yasunori; Miyake, Kentaro; Murakami, Takashi; Oshiro, Hiromichi; Igarashi, Kentaro; Kawaguchi, Kei; Hsu, John; Singh, Manish; Li, Yunfeng; Nelson, Scott; Bouvet, Michael; Singh,Shree Ram; Kanaya, Fuminori; Hoffman, Robert M
  3. Anticancer research. 2019, Sep; 39(9): 4775-4779.
  1. 8.   Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model
  2. Higuchi, Takashi; Miyake, Kentaro; Sugisawa, Norihiko; Oshiro, Hiromichi; Zhang, Zhiying; Razmjooei, Sahar; Yamamoto, Norio; Hayashi, Katsuhiro; Kimura, Hiroaki; Miwa, Shinji; Igarashi, Kentaro; Bouvet, Michael; Singh, Shree Ram; Tsuchiya, Hiroyuki; Hoffman, Robert M
  3. Cancer letters. 2019, Jun 1; 451: 122-127.
  1. 9.   Temozolomide targets and arrests a doxorubicin-resistant follicular dendritic-cell sarcoma patient-derived orthotopic xenograft mouse model
  2. Oshiro, Hiromichi; Tome, Yasunori; Kiyuna, Tasuku; Miyake, Kentaro; Kawaguchi, Kei; Higuchi, Takashi; Miyake, Masuyo; Zang, Zhiying; Razmjooei, Sahar; Barangi, Maryam; Wangsiricharoen, Sintawat; Nelson, Scott D; Li, Yunfeng; Bouvet, Michael; Singh,Shree Ram; Kanaya, Fuminori; Hoffman, Robert M
  3. Tissue & cell. 2019, Jun; 58: 17-23.
  1. 10.   The combination of olaratumab with gemcitabine and docetaxel arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft mouse model
  2. Higuchi, Takashi; Miyake, Kentaro; Sugisawa, Norihiko; Oshiro, Hiromichi; Zhang, Zhiying; Razmjooei, Sahar; Yamamoto, Norio; Hayashi, Katsuhiro; Kimura, Hiroaki; Miwa, Shinji; Igarashi, Kentaro; Bouvet, Michael; Singh,Shree Ram; Tsuchiya, Hiroyuki; Hoffman, Robert M.
  3. CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2019, Jun; 83(6): 1075-1082.
  1. 11.   Kaposi sarcoma
  2. Cesarman, Ethel; Damania, Blossom; Krown, Susan E.; Martin, Jeffrey; Bower, Mark; Whitby,Denise
  3. NATURE REVIEWS DISEASE PRIMERS. 2019, Jan 31; 5(1):
  1. 12.   Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcoma
  2. Igarashi, Kentaro; Kawaguchi, Kei; Kiyuna, Tasuku; Miyake, Kentaro; Miyaki, Masuyo; Yamamoto, Norio; Hayashi, Katsuhiro; Kimura, Hiroaki; Miwa, Shinji; Higuchi, Takashi; Singh, Arun S.; Chmielowski, Bartosz; Nelson, Scott D.; Russell, Tara A.; Eckardt, Mark A.; Dry, Sarah M.; Li, Yunfeng; Singh,Shree Ram; Chawla, Sant P.; Eilber, Fritz C.; Tsuchiya, Hiroyuki; Hoffman, Robert M.
  3. Biochemical and biophysical research communications. 2018, Dec 2; 506(4): 912-917.
  1. 13.   Oral Recombinant Methioninase Combined with Caffeine and Doxorubicin Induced Regression of a Doxorubicin-resistant Synovial Sarcoma in a PDOX Mouse Model
  2. Higuchi, Takashi; Kawaguchi, Kei; Miyake, Kentaro; Han, Qinghong; Tan, Yuying; Oshiro, Hiromichi; Sugisawa, Norihiko; Zhang, Zhiying; Razmjooei, Sahar; Yamamoto, Norio; Hayashi, Katsuhiro; Kimura, Hiroaki; Miwa, Shinji; Igarashi, Kentaro; Chawla, Sant P; Singh, Arun S; Eilber, Frederick C; Singh, Shree Ram; Tsuchiya, Hiroyuki; Hoffman, Robert M
  3. Anticancer research. 2018, Oct; 38(10): 5639-5644.
  1. 14.   Recombinant methioninase in combination with DOX overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma
  2. Igarashi, Kentaro; Kawaguchi, Kei; Li, Shukuan; Han, Qinghong; Tan, Yuying; Murakami, Takashi; Kiyuna, Tasuku; Miyake, Kentaro; Miyake, Masuyo; Singh, Arun S; Eckhardt, Mark A; Nelson, Scott D; Russell, Tara A; Dry, Sarah M; Li, Yunfeng; Yamamoto, Norio; Hayashi, Katsuhiro; Kimura, Hiroaki; Miwa, Shinji; Tsuchiya, Hiroyuki; Singh, Shree Ram; Eilber, Fritz C; Hoffman, Robert M
  3. Cancer Letters. 2018, MAR 28; 417: 168-173.
  1. 15.   Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes)
  2. Smith, B.; Lyakhov, I.; Loomis, K.; Needle, D.; Baxa, U.; Yavlovich, A.; Capala, J.; Blumenthal, R.; Puri, A.
  3. Journal of Controlled Release. 2011, Jul; 153(2): 187-194.
  1. 16.   Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma
  2. Uldrick, T. S.; Whitby, D.
  3. Cancer Letters. 2011, Jun; 305(2): 150-162.
  1. 17.   Fullerenol cytotoxicity in kidney cells is associated with cytoskeleton disruption, autophagic vacuole accumulation, and mitochondrial dysfunction
  2. Johnson-Lyles, D. N.; Peifley, K.; Lockett, S.; Neun, B. W.; Hansen, M.; Clogston, J.; Stern, S. T.; McNeil, S. E.
  3. Toxicology and Applied Pharmacology. 2010, Nov; 248(3): 249-258.
  1. 18.   Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv
  2. Loomis, K.; Smith, B.; Feng, Y.; Garg, H.; Yavlovich, A.; Campbell-Massa, R.; Dimitrov, D. S.; Blumenthal, R.; Xiao, X. D.; Puri, A.
  3. Experimental and Molecular Pathology. 2010, Apr; 88(2): 238-249.
  1. 19.   Nanomaterial standards for efficacy and toxicity assessment
  2. Adiseshaiah, P. P.; Hall, J. B.; McNeil, S. E.
  3. Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology. 2010, Jan-Feb; 2(1): 99-112.
  1. 20.   Various drug delivery approaches to the central nervous system
  2. Pasha, S.; Gupta, K.
  3. Expert Opinion on Drug Delivery. 2010, Jan; 7(1): 113-135.
  1. 21.   Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to Clinic
  2. Puri, A.; Loomis, K.; Smith, B.; Lee, J. H.; Yavlovich, A.; Heldman, E.; Blumenthal, R.
  3. Critical Reviews in Therapeutic Drug Carrier Systems. 2009 26(6): 523-580.
  1. 22.   Method for analysis of nanoparticle hemolytic properties in vitro
  2. Dobrovoiskaia, M. A.; Clogston, J. D.; Neun, B. W.; Hall, J. B.; Patri, A. K.; McNeil, S. E.
  3. Nano Letters. 2008 8(8): 2180-2187.
  1. 23.   HER2-Specific Affibody-Conjugated Thermosensitive Liposomes (Affisomes) for Improved Delivery of Anticancer Agents
  2. Puri, A.; Kramer-Marek, G.; Campbell-Massa, R.; Yavlovich, A.; Tele, S. C.; Lee, S. B.; Clogston, J. D.; Patri, A. K.; Blumenthal, R.; Capala, J.
  3. Journal of Liposome Research. 2008 18(4): 293-307.
  1. 24.   Rapid distribution of liposomal short-chain ceramide in vitro and in vivo
  2. Zolnik, B. S.; Stern, S. T.; Kaiser, J. M.; Heakal, Y.; Clogston, J. D.; Kester, M.; McNeil, S. E.
  3. Drug Metabolism and Disposition. 2008 36(8): 1709-1715.
  1. 25.   A model of drug delivery to normal and cancer cells by anti body-targeted nanoliposomes
  2. Sidorov, I. A.; Blumenthal, R.; Dimitrov, D. S.
  3. Journal of Computational and Theoretical Nanoscience. 2006, Jun; 3(3): 405-411.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel